Vaccinex, Inc.
VCNX$6M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaROCHESTER23 employees
Drugs in Pipeline
5
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
VCNX News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
Avelumab and Pepinemab
Metastatic Pancreatic Adenocarcinoma
VX15/2503 + avelumab
Carcinoma, Non-Small-Cell Lung
pepinemab + pembrolizumab
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
VX15/2503
Huntington's Disease
Pepinemab
Alzheimer Disease
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Avelumab and Pepinemab | Phase 2 | Metastatic Pancreatic Adenocarcinoma | - |
VX15/2503 + avelumab | Phase 2 | Carcinoma, Non-Small-Cell Lung | - |
pepinemab + pembrolizumab | Phase 2 | Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) | - |
VX15/2503 | Phase 2 | Huntington's Disease | - |
Pepinemab | Phase 2 | Alzheimer Disease | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply